Saul H. Rosenberg

22.4k citations

118 papers · 8.2k indexed · 2 hit papers · h-index 44

Co-authors: Haichao Zhang Steven W. Elmore Stephen K. Tahir Stephen W. Fesik Christin Tse Alexander R. Shoemaker Xiufen Yang Shi‐Chung Ng
Topics: Cancer-related Molecular Pathways (23 papers)Cell death mechanisms and regulation (22 papers)DNA Repair Mechanisms (20 papers)
Cited by: Oncology Molecular Biology Organic Chemistry
Journals: Science Journal of Biological Chemistry Blood
Partner nations: United States United Kingdom China

In The Last Decade

Saul H. Rosenberg

117 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

2008 1.5k citations Christin Tse, Alexander R. Shoemaker et al. Cancer Research profile →
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

2010 663 citations Wyndham H. Wilson, Owen A. O’Connor et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Saul H. Rosenberg

Since Specialization

Citations

This map shows the geographic impact of Saul H. Rosenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saul H. Rosenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saul H. Rosenberg more than expected).

Fields of papers citing papers by Saul H. Rosenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Saul H. Rosenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saul H. Rosenberg. The network helps show where Saul H. Rosenberg may publish in the future.

Co-authorship network of co-authors of Saul H. Rosenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Saul H. Rosenberg. A scholar is included among the top collaborators of Saul H. Rosenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Saul H. Rosenberg. Saul H. Rosenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo 2011 ·Molecular Cancer Therapeutics ·Jun Chen,Sha Jin,(unknown),Xiaoli Huang,Bernard A. Liu,Michael J. Mitten,Paul Nimmer,Xiaoyu Lin,Morey L. Smith,Yu Shen,Alexander R. Shoemaker,Stephen K. Tahir,Haichao Zhang,Scott Ackler,Saul H. Rosenberg,Heather Maecker,Deepak Sampath,Joel Johansson,Chris Tse,Steven W. Elmore	119
2	Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines 2010 ·Molecular Cancer Therapeutics ·Stephen K. Tahir,John Wass,Mary K. Joseph,Viswanath Devanarayan,Paul Hessler,Haichao Zhang,Steve W. Elmore,Paul E. Kroeger,Christin Tse,Saul H. Rosenberg,Mark G. Anderson	59
3	A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax) 2010 ·Molecular Cancer Therapeutics ·Lloyd T. Lam,Xin Lü,Haichao Zhang,Rick Lesniewski,Saul H. Rosenberg,Dimitri Semizarov	44
4	Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activitybreakdown → 2010 ·The Lancet Oncology ·Wyndham H. Wilson,Owen A. O’Connor,Myron S. Czuczman,Ann S. LaCasce,John F. Gerecitano,John P. Leonard,Anil Tulpule,Kieron Dunleavy,Hao Xiong,Yi‐Lin Chiu,Yue Cui,Todd Busman,Steven W. Elmore,Saul H. Rosenberg,Andrew Krivoshik,Sari H. Enschede,Rod Humerickhouse	663
5	ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors 2009 ·Clinical Cancer Research ·Joann P. Palma,Yichun Wang,Luis E. Rodrı́guez,Debra Montgomery,Peter Ellis,Gail Bukofzer,(unknown),Xuesong Liu,Yan Shi,Loren Lasko,Gui‐Dong Zhu,Thomas D. Penning,Vincent L. Giranda,Saul H. Rosenberg,David J. Frost,Cherrie K. Donawho	111
6	Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways 2009 ·Molecular Cancer Research ·Xuesong Liu,Edward K. Han,Mark G. Anderson,Yan Shi,Dimitri Semizarov,Gang Wang,Thomas McGonigal,Lisa Roberts,Loren Lasko,Joann P. Palma,Gui‐Dong Zhu,Thomas D. Penning,Saul H. Rosenberg,Vincent L. Giranda,Yan Luo,Joel Johansson,Eric F. Johnson,Alexander R. Shoemaker	77
7	ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitorbreakdown → 2008 ·Cancer Research ·Christin Tse,Alexander R. Shoemaker,Jessica Adickes,Mark G. Anderson,Jun Chen,Sha Jin,Eric F. Johnson,Kennan C. Marsh,Michael J. Mitten,Paul Nimmer,Lisa Roberts,Stephen K. Tahir,Xiao Yu,Xiufen Yang,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore	1513
8	ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo 2008 ·Molecular Cancer Therapeutics ·Scott Ackler,Xiao Yu,Michael J. Mitten,Kelly Foster,Anatol Oleksijew,Marion Refici,(unknown),Baole Wang,Sanjay R. Chemburkar,Joy Bauch,Christin Tse,David J. Frost,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore,Alex R. Shoemaker	64
9	Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737 2007 ·Cancer Research ·Stephen K. Tahir,Xiufen Yang,Mark G. Anderson,Susan E. Morgan-Lappe,Aparna V. Sarthy,Jun Chen,Robert B. Warner,Shi‐Chung Ng,Stephen W. Fesik,Steve W. Elmore,Saul H. Rosenberg,Christin Tse	250
10	Cyanopyridyl containing 1,4-dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: Improving oral biovailability 2007 ·Bioorganic & Medicinal Chemistry Letters ·Yunsong Tong,(unknown),Zhi‐Fu Tao,Jennifer J. Bouska,Kent D. Stewart,Chang Park,Gaoquan Li,Akiyo Claiborne,Peter Kovar,Zehan Chen,Philip J. Merta,(unknown),Amanda M. Olson,Donald J. Osterling,Haiying Zhang,Hing L. Sham,Saul H. Rosenberg,Thomas J. Sowin,Nan‐Horng Lin	5
11	Macrocyclic ureas as potent and selective Chk1 inhibitors: An improved synthesis, kinome profiling, structure–activity relationships, and preliminary pharmacokinetics 2007 ·Bioorganic & Medicinal Chemistry Letters ·Zhi‐Fu Tao,Zehan Chen,(unknown),Peter Kovar,Eric F. Johnson,Jennifer J. Bouska,Haiying Zhang,Saul H. Rosenberg,Thomas J. Sowin,Nan‐Horng Lin	13
12	Design and synthesis of pyridine–pyrazolopyridine-based inhibitors of protein kinase B/Akt 2007 ·Bioorganic & Medicinal Chemistry ·Gui‐Dong Zhu,Jianchun Gong,Viraj B. Gandhi,Keith W. Woods,Yan Luo,Xuesong Liu,Ran Guan,Vered Klinghofer,Eric F. Johnson,Vincent S. Stoll,Mulugeta Mamo,Qun Li,Saul H. Rosenberg,Vincent L. Giranda	58
13	Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-x _L from NMR and Parallel Synthesis 2005 ·Journal of Medicinal Chemistry ·Andrew M. Petros,Jürgen Dinges,David J. Augeri,(unknown),David A. Betebenner,Mark G. Bures,Steven W. Elmore,Philip J. Hajduk,Mary K. Joseph,(unknown),David G. Nettesheim,Saul H. Rosenberg,Shen Wang,Sheela A. Thomas,Xilu Wang,(unknown),Haichao Zhang,Stephen W. Fesik	229
14	Benzimidazolones and indoles as non-thiol farnesyltransferase inhibitors based on tipifarnib scaffold: synthesis and activity 2005 ·Bioorganic & Medicinal Chemistry Letters ·Qun Li,Tongmei Li,Keith W. Woods,Wen‐Zhen Gu,Jerry D. Cohen,Vincent S. Stoll,(unknown),Charles W. Hutchins,David J. Frost,Saul H. Rosenberg,Hing L. Sham	66
15	A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation 2004 ·Oncogene ·Zhan Xiao,John Xue,Thomas J. Sowin,Saul H. Rosenberg,Haiying Zhang	73
16	Distinctive Roles of PHAP Proteins and Prothymosin-α in a Death Regulatory Pathway 2003 ·Science ·Xuejun Jiang,Hyun-Eui Kim,Hongjun Shu,Yingming Zhao,Haichao Zhang,James L. Kofron,(unknown),Dave Burns,ShiChung Ng,Saul H. Rosenberg,Xiaodong Wang	316
17	Synthesis and biological evaluation of 4-[(3-Methyl-3H-imidazol-4-yl)-(2-phenylethynyl-benzyloxy)-methyl]-benzonitrile as novel farnesyltransferase inhibitor 2003 ·Bioorganic & Medicinal Chemistry Letters ·Nan‐Horng Lin,Le Wang,Jerry D. Cohen,Wen‐Zhen Gu,David J. Frost,Haiying Zhang,Saul H. Rosenberg,Hing L. Sham	4
18	Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides 1993 ·Journal of Medicinal Chemistry ·Saul H. Rosenberg,Kenneth P. Spina,Keith W. Woods,(unknown),(unknown),Zhu Yao,Herman H. Stein,Jerome Cohen,(unknown)	46
19	Studies directed toward the design of orally active renin inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (2S)-2-benzyl-3-[[(1-methylpiperazin-4-yl)sulfonyl]propionyl]-3-thiazol-4-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane (A-72517) 1993 ·Journal of Medicinal Chemistry ·Saul H. Rosenberg,Kenneth P. Spina,(unknown),(unknown),Zhu Yao,Peter Kovar,Herman H. Stein,Jerome D. Cohen,(unknown)	36
20	Potent, low molecular weight renin inhibitors containing a C-terminal heterocycle: hydrogen bonding at the active site 1990 ·Journal of Medicinal Chemistry ·Saul H. Rosenberg,Joseph F. Dellaria,Dale J. Kempf,Charles W. Hutchins,Keith W. Woods,Robert G. Maki,(unknown),Kenneth P. Spina,Herman H. Stein	17

About Saul H. Rosenberg

Saul H. Rosenberg is a scholar working on Oncology, Molecular Biology and Organic Chemistry, having authored 118 papers that have together received 8.2k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (23 papers), Cell death mechanisms and regulation (22 papers) and DNA Repair Mechanisms (20 papers). The work is most often cited by research in Oncology (2.3k citations), Molecular Biology (5.6k citations) and Organic Chemistry (1.7k citations). Saul H. Rosenberg has collaborated with scholars based in United States, United Kingdom and China. Frequent co-authors include Haichao Zhang, Steven W. Elmore, Stephen K. Tahir, Stephen W. Fesik, Christin Tse, Alexander R. Shoemaker, Xiufen Yang, Shi‐Chung Ng, Jun Chen and Paul Nimmer. Their work appears in journals such as Science, Journal of Biological Chemistry and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact